Ms. Turner was President and CEO of Carmot Therapeutics from January 2023 to June 2024. From September 2022 to December 2022 she was COO. As CEO she completed a $150 million cross over round of financing and well as successfully orchestrated a dual track IPO/strategic transaction process which ultimately resulted in the acquisition of Carmot by Roche for $3.1 billion. In addition to the transactions, Ms. Turner also built a very successful team growing Carmot from approximately 35 people to approximately 70 people which included leadership in key functions such as CMC, Quality, Finance, Legal and HR. Before Carmot, Ms. Turner served as Chief General Counsel and Secretary at Lyell Immunopharma, Inc. Notably, she oversaw the execution of the company’s $400 million Series C financing and the fourth largest Nasdaq IPO which raised gross proceeds of approximately $425 million. In addition, Ms. Turner oversaw numerous strategic partnerships including the Company’s development and commercialization partnership with GSK which included a $200 million investment. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. a publicly traded gene therapy and gene editing company. Ms. Turner served as Executive Vice President, General Counsel and Head of Portfolio Strategy at Atara Biotherapeutics, Inc., a publicly-traded allogeneic cell therapy company. At Atara, in addition to legal and portfolio strategy, Ms. Turner oversaw human resources as well as medical affairs. Prior to Atara, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a publicly-traded company focused on metabolic diseases. During her tenure at Orexigen, Ms. Turner oversaw the legal, human resources, government affairs and facilities functions. Ms. Turner started her career at Cooley as a corporate securities associate. Ms. Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara.
